Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7995990 | 0.86 | KCNH2 (0.80) | MAPTKCNH2HTR7KMT2ALMNA | |
| SCHEMBL15445827 | 0.82 | MAPT (0.66) | MAPTKCNH2SIGMAR1HTR7KMT2A | |
| SCHEMBL8079721 | 0.81 | MAPT (0.52) | MAPTKCNH2HTR7KMT2ALMNA | |
| SCHEMBL13656461 | 0.81 | MAPT (0.52) | MAPTKCNH2HTR7KMT2ALMNA | |
| SCHEMBL325609 | 0.80 | SIGMAR1 (0.72) | MAPTKCNH2SIGMAR1KMT2A | |
| SCHEMBL12576443 | 0.77 | MAPT (0.82) | MAPTKCNH2HTR7KMT2ALMNA | |
| SCHEMBL12575380 | 0.77 | MAPT (0.82) | MAPTKCNH2HTR7KMT2ALMNA | |
| SCHEMBL7997482 | 0.75 | KCNH2 (1.00) | MAPTKCNH2HTR7KMT2ALMNA | |
| SCHEMBL7997532 | 0.75 | KCNH2 (1.00) | MAPTKCNH2HTR7KMT2ALMNA | |
| SCHEMBL5741708 | 0.75 | MAPT (0.66) | MAPTKMT2ALMNASMN1; SMN2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | MAPT 2536/4885KCNH2 135/4885SIGMAR1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.